ReviewInternational journal of general medicine2026
Molecular Mechanisms and Clinical Applications of Buyang Huanwu Decoction in the Treatment of Ischemic Stroke: A Review.
Review in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke (IS) is a severe cerebrovascular disease characterized by high incidence, disability, and mortality rates. Despite continuous advancements in medical technology, the clinical treatment of IS continues to face significant challenges. The pathological mechanisms of IS are complex and diverse, involving processes such as oxidative stress, neuroinflammation, and apoptosis. Traditional Chinese Medicine (TCM), a longstanding therapeutic system, has demonstrated unique advantages in IS treatment. The classical formula Buyang Huanwu Decoction (BYHWD) has become a commonly used prescription for treating stroke and its sequelae, particularly in East Asia. BYHWD, through its multi-pathway and multi-target mechanisms of action, can significantly enhance treatment efficacy while reducing adverse reactions. Exploring the molecular mechanisms of BYHWD offers the potential for a more comprehensive therapeutic strategy for global patients suffering from IS. This article outlines the key signaling pathways and therapeutic targets involved in the treatment of IS with BYHWD, including the PI3K-Akt pathway, autophagy, Nrf2, VEGF, inflammasome, the Notch pathway, NF-κB, and ferroptosis. Additionally, it summarizes the role of BYHWD in ameliorating neurological deficits through the regulation with synaptic plasticity, as well as the current progress in clinical applications and the development and utilization status of its derived preparations. This review aims to provide a solid theoretical foundation for further in-depth research and development of BYHWD, guiding the development of anti-IS drugs based on the holistic treatment concept of TCM formulas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.